Neuropsychological tests (NPTs), which are routinely used in clinical practice for assessment of dementia, are also considered to be essential for differential diagnosis of Alzheimer's disease (AD) and frontotemporal lobar degeneration (FTLD), especially the behavioral variants of frontotemporal dementia (bvFTD) and primary progressive aphasia (PPA) at their initial clinical presentations. However, the heterogeneous features of these diseases, which have many overlapping signs, make differentiation between AD and FTLD highly challenging. Moreover, NPTs were primarily developed in Western countries and for native speakers of non-tonal languages. Hence, there is an ongoing dispute over the validity and reliability of these tests in culturally different and typologically diverse language populations. The purpose of this case series was to examine which of the NPTs adjusted for Taiwanese society may be used to distinguish these two diseases. Since AD and FTLD have different effects on individuals' brain, we combined NPTs with neuroimaging. We found that participants diagnosed with FTLD had lower scores in NPTs assessing language or social cognition than AD participants. PPA participants also had lower measures in the Free and Cued Selective Reminding Test than those diagnosed with bvFTD, while bvFTD participants showed poorer performances in the behavioral measures than PPA participants. In addition, the initial diagnosis was supported by the standard one-year clinical follow-up.

College of Medicine China Medical University Taichung 404327 Taiwan

Department of Functional Materials Institute of Physics Czech Academy of Sciences 18200 Prague Czech Republic

Department of Neurology and Centre of Clinical Neuroscience 1st Faculty of Medicine and General University Hospital Prague Charles University 12108 Prague Czech Republic

Department of Neurology China Medical University Hospital Taichung 404327 Taiwan

Department of Psychiatry China Medical University Hospital Taichung 404327 Taiwan

Zobrazit více v PubMed

Alzheimer’s Association . Alzheimer’s Disease Facts and Figures. Alzheimer’s Association; Chicago, IL, USA: 2021. [(accessed on 5 February 2021)]. Available online: https://www.alz.org/media/documents/alzheimers-facts-and-figures.pdf.

Kuo C.Y., Hsiao H.T., Lo I.H., Nikolai T. Association between obstructive sleep apnea, its treatment, and Alzheimer’s disease: Systematic mini-review. Front. Aging Neurosci. 2021;12:591737. doi: 10.3389/fnagi.2020.591737. PubMed DOI PMC

Rodriguez J.L., Karikari T., Suárez-Calvet M., Troakes C., King A., Emersic A., Aarsland D., Hye A., Zetterberg H., Blennow K., et al. Plasma p-tau181 accurately predicts Alzheimer’s disease pathology at least 8 years prior to post-mortem and improves the clinical characterization of cognitive decline. Acta Neuropathol. 2020;140:267–278. doi: 10.1007/s00401-020-02195-x. PubMed DOI PMC

Singh-Manoux A., Dugravot A., Fournier A., Abell J., Ebmeier K., Kivimaki M., Sabia S. Trajectories of depressive symptoms before diagnosis of dementia: A 28-year follow-up study. JAMA Psychiatry. 2017;74:712–718. doi: 10.1001/jamapsychiatry.2017.0660. PubMed DOI PMC

Villain N., Dubois B. Alzheimer’s disease including focal presentations. Semin. Neurol. 2019;39:213–226. doi: 10.1055/s-0039-1681041. PubMed DOI

Kivipelto M., Mangialasche F., Ngandu T. Lifestyle interventions to prevent cognitive impairment, dementia and Alzheimer’s disease. Nat. Rev. Neurol. 2018;14:653–666. doi: 10.1038/s41582-018-0070-3. PubMed DOI

Kuo C.Y., Stachiv I., Nikolai T. Association of Late Life Depression, (Non-) Modifiable Risk and Protective Factors with Dementia and Alzheimer’s Disease: Literature Review on Current Evidences, Preventive Interventions and Possible Future Trends in Prevention and Treatment of Dementia. Int. J. Environ. Res. Public Health. 2020;17:7475. doi: 10.3390/ijerph17207475. PubMed DOI PMC

Cummings J.L., Tong G., Ballard C. Treatment combinations for Alzheimer’s disease: Current and future pharmacotherapy options. J. Alzheimer’s Dis. 2019;67:779–794. doi: 10.3233/JAD-180766. PubMed DOI PMC

Frozza R.L., Lourenco M.V., De Felice F.G. Challenges for Alzheimer’s disease therapy: Insight from novel mechanisms beyond memory defects. Front. Neorosci. 2018;12:37. doi: 10.3389/fnins.2018.00037. PubMed DOI PMC

Rasmussen J., Langerman H. Alzheimer’s disease—Why we need early diagnosis. Degener. Neurol. Neuromuscul Dis. 2019;9:123–130. doi: 10.2147/DNND.S228939. PubMed DOI PMC

Karran E., De Strooper B. The amyloid hypothesis in Alzheimer disease: New insights from new therapeutics. Nat. Rev. Drug Discov. 2022;21:306–318. doi: 10.1038/s41573-022-00391-w. PubMed DOI

Knopman D.S., Jones D.T., Greicius M.D. Failure to demonstrate efficacy of aducanumab: An analysis of the EMERGE and ENGAGE trials as reported by Biogen, December 2019. Alzheimers Dement. 2021;17:696–701. doi: 10.1002/alz.12213. PubMed DOI

Di Costanzo A., Paris D., Melck D., Angiolillo A., Corso G., Maniscalco M., Motta A. Blood biomarkers indicate that the preclinical stages of Alzheimer’s disease present overlapping molecular features. Sci. Rep. 2020;10:15612. doi: 10.1038/s41598-020-71832-y. PubMed DOI PMC

Gauthier S., Reisberg B., Zaudig M., Petersen R.C., Ritchie K., Broich K., Belleville S., Brodaty H., Bennett D., Chertkow H., et al. International Psychogeriatric Association Expert Conference on mild cognitive impairment. Mild cognitive impairment. Lancet. 2006;367:1262–1270. doi: 10.1016/S0140-6736(06)68542-5. PubMed DOI

Draper B., Cations M., White F., Trollor J., Loy C., Brodaty H., Sachdev P., Gonski P., Demirkol A., Cumming R.G., et al. Time of diagnosis in young-onset dementia and its determinants: The INSPIRED study. Int. J. Geriatr. Psychiatry. 2016;31:1217–1224. doi: 10.1002/gps.4430. PubMed DOI

Onyike C.U., Diehl-Schmid J. The epidemiology of frontotemporal dementia. Int. Rev. Psychiatry. 2013;25:130–137. doi: 10.3109/09540261.2013.776523. PubMed DOI PMC

Katisko K., Cajanus A., Korhonen T., Remes A.M., Haapasalo A., Solje E. Prodromal and Early bvFTD: Evaluating Clinical Features and Current Biomarkers. Front. Neurosci. 2019;13:658. doi: 10.3389/fnins.2019.00658. PubMed DOI PMC

Nichols E., Szoeke C.E., Vollset S.E., Abbasi N., Abd-Allah F., Abdela J., Aichour M.T.E., Akinyemi R.O., Alahdab F., Asgedom S.W., et al. Global, regional, and national burden of Alzheimer’s disease and other dementias, 1990–2016: S systematic analysis for the Global burden of disease study 2016. Lancet Neurol. 2019;18:88–106. doi: 10.1016/S1474-4422(18)30403-4. PubMed DOI PMC

Reul S., Lohmann H., Weindl H., Duning T., Johnen A. Can cognitive assessment really discriminate early stages of Alzheimer’s disease and behavioral variant frontotemporal dementia at initial clinical presentation? Alzheimers Res. Ther. 2017;9:61. doi: 10.1186/s13195-017-0287-1. PubMed DOI PMC

Krudop W.A., Dols A., Kerssens C.J., Eikelenboom P., Prins N.D., Möller C., Schouws S., Rhebergen D., van Exel E., van der Flier W.M., et al. The pitfall of behavioral variant frontotemporal dementia mimics despite multidisciplinary application of the FTDC criteria. J. Alzheimer’s Dis. 2017;60:959–975. doi: 10.3233/JAD-170608. PubMed DOI

Musa G., Slachevsky A., Muñoz-Neira C., Méndez-Orellana C., Villagra R., González-Billault C., Ibáñez A., Hornberger M., Lillo P. Alzheimer’s Disease or Behavioral Variant Frontotemporal Dementia? Review of Key Points Toward an Accurate Clinical and Neuropsychological Diagnosis. J. Alzheimer’s Dis. 2020;73:833–843. doi: 10.3233/JAD-190924. PubMed DOI PMC

Mendez M.F., Shapira J.S., McMurtray A., Licht E., Miller B.L. Accuracy of the Clinical Evaluation for Frontotemporal Dementia. Arch. Neurol. 2007;64:830–835. doi: 10.1001/archneur.64.6.830. PubMed DOI

Leroy M., Bertoux M., Skrobala E., Mode E., Adnet-Bonte C., Le Ber I., Bombois S., Cassagnaud P., Chen Y., Deramecourt V., et al. Characteristics and progression of patients with frontotemporal dementia in a regional memory clinic network. Alz. Res. Therapy. 2021;13:19. doi: 10.1186/s13195-020-00753-9. PubMed DOI PMC

Ducharme S., Dols A., LaForce R., Devenney E., Kumfor F., Stock J.V.D., Dallaire-Théroux C., Seelaar H., Gossink F., Vijverberg E., et al. Recommendations to distinguish behavioral variant frontotemporal dementia from psychiatric disorders. Brain. 2020;143:1632–1650. doi: 10.1093/brain/awaa018. PubMed DOI PMC

Ma D., Lu D., Popuri K., Wang L., Beg M.F., Alzheimer’s Disease Neuroimaging Initiative Differential Diagnosis of Frontotemporal Dementia, Alzheimer’s Disease, and Normal Aging Using a Multi-Scale Multi-Type Feature Generative Adversarial Deep Neural Network on Structural Magnetic Resonance Images. Front. Neurosci. 2020;14:853. doi: 10.3389/fnins.2020.00853. PubMed DOI PMC

Johnen A., Bertoux M. Psychological and cognitive markers of behavioral variant frontotemporal dementia- A clinical neuropsychologist’s view on diagnostic criteria and beyond. Front. Neurol. 2019;10:594. doi: 10.3389/fneur.2019.00594. PubMed DOI PMC

Ng K.P., Chiew H.J., Lim L., Rosa-Neto P., Kandiah N., Gauthier S. The influence of language and culture on cognitive assessment tools in the diagnosis of early cognitive impairment and dementia. Expert Rev. Neurother. 2018;18:859–869. doi: 10.1080/14737175.2018.1532792. PubMed DOI

Li H., Li C., Wang A., Qi Y., Feng W., Hou C., Tao L., Liu X., Li X., Wang W., et al. Associations between social and intellectual activities with cognitive trajectories in Chinese middle-aged and older adults: A nationally representative cohort study. Alz. Res. Therapy. 2020;12:115. doi: 10.1186/s13195-020-00691-6. PubMed DOI PMC

American Psychiatric Association . The Diagnostic and Statistical Manual of Mental Disorders. 5th ed. American Psychiatric Association; Washington, DC, USA: 2013. p. 607.

Daugherty J.C., Puente A.E., Fasfous A.F., Hidalgo-Ruzzante N., Perez-Garcia M. Diagnostic mistakes of culturally diverse individuals when using North American neuropsychological tests. Appl. Neuropsychol. Adult. 2017;24:16–22. doi: 10.1080/23279095.2015.1036992. PubMed DOI

Wu Y.-T., Brayne C., Matthews F.E. Prevalence of dementia in East Asia: A systematic review of time trends. Int. J. Geriatr. Psychiatry. 2015;30:793–801. doi: 10.1002/gps.4297. PubMed DOI PMC

Kucukguc O., Soylemez B.A., Yener G., Barutcu C.D., Akyol M.A. Examining factors affecting caregiver burden: A comparison of frontotemporal dementia and Alzheimer’s disease. Am. J. Alzheimer’s Dis. Other Dement. 2017;32:200–206. doi: 10.1177/1533317517703479. PubMed DOI PMC

Wong H.Y., Zhong H., Zhong M., Zhou X., Chan P.Y.C., Kwok T.C.Y., Mok K., Hardy J., Ip F.C., Fu A.K., et al. Demographics and medication use of patients with late-onset Alzheimer’s disease in Hong Kong. J. Alzheimers Dis. 2022;87:1205–1213. doi: 10.3233/JAD-215312. PubMed DOI PMC

Zhao S., Guo C., Wang M., Chen W., Wu Y., Tang W. A clinical memory battery for screening for mild cognitive impairment in elderly Chinese population. J. Clin. Neurosci. 2011;18:774–779. doi: 10.1016/j.jocn.2010.07.149. PubMed DOI

Lee J.-Y., Lee D.W., Cho S.-J., Na D.L., Jeon H.J., Kim S.-K., Lee Y.R., Youn J.-H., Kwon M., Lee J.-H., et al. Brief Screening for Mild Cognitive Impairment in Elderly Outpatient Clinic: Validation of the Korean Version of the Montreal Cognitive Assessment. J. Geriatr. Psychiatry Neurol. 2008;21:104–110. doi: 10.1177/0891988708316855. PubMed DOI

Chen K.-L., Xu Y., Chu A.-Q., Ding D., Liang X.-N., Nasreddine Z.S., Dong Q., Hong Z., Zhao Q.-H., Guo Q.-H. Validation of the Chinese version of Montreal cognitive assessment basic for screening mild cognitive impairment. J. Am. Geriatr. Soc. 2016;64:e285–e290. doi: 10.1111/jgs.14530. PubMed DOI

Wang F., Zhou A., Wei C., Zuo X., Ma X., Zhao L., Jin H., Li Y., Guo D., Jia J. Good performance of the Chinese Version of Mini social cognition and emotional assessment in the early diagnosis of behavioral variant frontotemporal dementia. Front. Neurol. 2022;13:827945. doi: 10.3389/fneur.2022.827945. PubMed DOI PMC

Swift I.J., Sogorb-Esteve A., Heller C., Synofzik M., Otto M., Graff C., Galimberti D., Todd E., Heslegrave A.J., van der Ende E.L., et al. Fluid biomarkers in frontotemporal dementia: Past, present and future. J. Neurol. Neurosurg. Psychiatry. 2021;92:204–215. doi: 10.1136/jnnp-2020-323520. PubMed DOI

Stachiv I., Kuo C.-Y., Li W. Protein adsorption by nanomechanical mass spectrometry: Beyond the real-time molecular weighting. Front. Mol. Biosci. 2023;9:1058441. doi: 10.3389/fmolb.2022.1058441. PubMed DOI PMC

Albert M.S., DeKosky S.T., Dickson D., Dubois B., Feldman H.H., Fox N.C., Gamst A., Holtzman D.M., Jagust W.J., Petersen R.C., et al. The diagnosis of mild cognitive impairment due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7:270–279. doi: 10.1016/j.jalz.2011.03.008. PubMed DOI PMC

Cohen A.D., Landau S.M., Snitz B.E., Klunk W.E., Blennow K., Zetterberg H. Fluid and PET biomarkers for amyloid pathology in Alzheimer’s disease. Mol. Cell. Neurosci. 2019;97:3–17. doi: 10.1016/j.mcn.2018.12.004. PubMed DOI

Albert M., DeCarli C., DeKosky S., de Leon M., Foster N.L., Fox N., Frank R., Frackowiak R., Jack C., Jagus W.J., et al. The use of MRI and PET for clinical diagnosis of dementia and investigation of cognitive impairment: A consensus report. [(accessed on 15 September 2022)];Alzheimer’s Assoc. Neuroimaging Work Gr. Consens. Rep. 2005 1:1–15. Available online: http://www.alz.org/national/documents/imaging_consensus_report.pdf.

Staffaroni A.M., Elahi F.M., McDermott D., Marton K., Karageorgiou E., Sacco S. Neuroimiging in Dementia. Semin. Neurol. 2017;37:510–537. doi: 10.1055/s-0037-1608808. PubMed DOI PMC

Qi W., Sun X., Hong Y. Normative Data for Adult Mandarin-Speaking Populations: A Systematic Review of Performance-Based Neuropsychological Instruments. J. Int. Neuropsychol. Soc. 2022;28:520–540. doi: 10.1017/S1355617721000667. PubMed DOI

Bora E., Walterfang M., Velakoulis D. Theory of mind in behavioural-variant frontotemporal dementia and Alzheimer’s disease: A meta-analysis. J. Neurol. Neurosurg. Psychiatry. 2015;86:714–719. doi: 10.1136/jnnp-2014-309445. PubMed DOI

Giovagnoli A.R., Bell B., Erbetta A., Paterlini C., Bugiani O. Analyzing theory of mind impairment in patients with behavioral variant frontotemporal dementia. Neurol. Sci. 2019;40:1893–1900. doi: 10.1007/s10072-019-03911-6. PubMed DOI

Varma A.R., Adams W., Lloyd J.J., Carson K.J., Snowden J.S., Testa H.J., Jackson A., Neary D. Diagnostic patterns of regional atrophy on MRI and regional cerebral blood flow change on SPECT in young onset patients with Alzheimer’s disease, frontotemporal dementia and vascular dementia. Acta Neurol. Scand. 2002;105:261–269. doi: 10.1034/j.1600-0404.2002.1o148.x. PubMed DOI

Valotassiou V., Malamitsi J., Papatriantafyllou J., Dardiotis E., Tsougos I., Psimadis D., Alexiou S., Hadjigeorgiou G., Georgoulias P. SPECT and PET imaging in Alzheimer’s disease. Ann. Nucl. Med. 2018;32:583–593. doi: 10.1007/s12149-018-1292-6. PubMed DOI

Rivas-Fernández M.A., Lindín M., Zurrón M., Diaz F., Aldrey-Vázquez J.M., Pías-Peleteiro J.M., Vázquez-Vázquez L., Pereiro A.X., Lojo-Seoane C., Nieto-Vieites A., et al. Brain Atrophy and Clinical Characterization of Adults With Mild Cognitive Impairment and Different Cerebrospinal Fluid Biomarker Profiles According to the AT(N) Research Framework of Alzheimer’s Disease. Front. Hum. Neurosci. 2022;16:799347. doi: 10.3389/fnhum.2022.799347. PubMed DOI PMC

Petersen R.C., Caracciolo B., Brayne C., Gauthier S., Jelic V., Fratiglioni L. Mild cognitive impairment: A concept in evaluation. J. Intern. Med. 2014;275:214–228. doi: 10.1111/joim.12190. PubMed DOI PMC

Chare L., Hodges J.R., Leyton C.E., McGinley C., Tan R.H., Kril J.J., Halliday G.M. New criteria for frontotemporal dementia syndromes: Clinical and pathological diagnostic implications. J. Neurol. Neurosurg. Psychiatry. 2014;85:866–871. doi: 10.1136/jnnp-2013-306948. PubMed DOI

Folstein M.F., Folstein S.E., McHugh P.R. “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J. Psychiatr. Res. 1975;12:189–198. doi: 10.1016/0022-3956(75)90026-6. PubMed DOI

Nasreddine Z.S., Phillips N.A., Bédirian V., Charbonneau S., Whitehead V., Collin I., Cummings J.L., Chertkow H. The Montreal Cognitive Assessment, MoCA: A brief screening tool for mild cognitive impairment. J. Am. Geriatr. Soc. 2005;53:695–699. doi: 10.1111/j.1532-5415.2005.53221.x. PubMed DOI

Kertesz A., Davidson W., Fox H. Frontal Behavioral Inventory: Diagnostic criteria for frontal lobe dementia. Can. J. Neurol. Sci. 1997;24:29–36. doi: 10.1017/S0317167100021053. PubMed DOI

Mesulam M.M. Primary progressive aphasia. Ann. Neurol. 2001;49:425–432. doi: 10.1002/ana.91. PubMed DOI

Marshall C.R., Hardy C.J.D., Volkmer A., Russell L.L., Bond R.L., Fletcher P.D., Clark C.N., Mummery C.J., Schott J.M., Rossor M.N., et al. Primary progressive aphasia: A clinical approach. J. Neurol. 2018;265:1474–1490. doi: 10.1007/s00415-018-8762-6. PubMed DOI PMC

Liu X., Wang W., Wang H., Sun Y. Sentence comprehension in patients with dementia of the Alzheimer’s type. PeerJ. 2019;7:e8181. doi: 10.7717/peerj.8181. PubMed DOI PMC

O’Bryant S.E., Waring S.C., Cullum C.M., Hall J., Lacritz L., Massman P.J., Lupo P.J., Reisch J.S., Doody R., Texas Alzheimer’s Research Consortium Stating dementia using clinical dementia rating scale sum of boxes scores. Arch. Neurol. 2008;65:1091–1095. doi: 10.1001/archneur.65.8.1091. PubMed DOI PMC

Sahakian B.J., Morris R.G., Evenden J.L., Heald A., Levy R., Philpot M., Robbins T.W. A Comparative Study of Visuospatial Memory and Learning in Alzheimer-Type Dementia and Parkinson’s Disease. Brain. 1988;111:695–718. doi: 10.1093/brain/111.3.695. PubMed DOI

Chung S.-Y., Hua M.-S., Hsuech H.-C., Chang Y.-S., Chiu C.-F., Chen M.-C. The Performance Pattern of Normal Illiterate and Patients with Early Alzheimer’s Disease on the Semantic Association of Verbal Fluency Test. Chin. J. Psychol. 2007;49:73–86. doi: 10.6129/CJP.2007.4901.05. DOI

Zarino B., Crespi M., Launi M., Casarotti A. A new standardization of semantic verbal fluency test. Neurol. Sci. 2014;35:1405–1411. doi: 10.1007/s10072-014-1729-1. PubMed DOI

Johnen A., Frommever J., Modes F., Wiendl H., Duning T., Lohmann H. Dementia Apraxia Test (DATE): A Brief Tool to Differentiate Behavioral Variant Frontotemporal Dementia from Alzheimer’s Dementia Based on Apraxia Profiles. J. Alzheimer’s Dis. 2016;49:593–605. doi: 10.3233/JAD-150447. PubMed DOI

Gregory C., Lough S., Stone V., Erzinclioglu S., Martin L., Baron-Cohen S., Hodges J.R. Theory of mind in patients with frontal variant frontotemporal dementia and Alzheimer’s disease: Theoretical and practical implications. Brain. 2002;125:752–764. doi: 10.1093/brain/awf079. PubMed DOI

Grober E., Sanders A.E., Hall C., Lipton R.B. Free and Cued Selective Reminding Identifies Very Mild Dementia in Primary Care. Alzheimer Dis. Assoc. Disord. 2010;24:284–290. doi: 10.1097/WAD.0b013e3181cfc78b. PubMed DOI PMC

Lezak M., Howieson D., Bigler E., and Tranel D. Neuropsychological Assessment. Oxford University Press; New York, NY, USA: 2012.

Montembeault M., Brambati S.M., Gorno-Tempini M.L., Migliaccio R. Clinical, anatomical, and pathological features in the three variants of primary progressive Aphasia: A review. Front. Neurol. 2018;9:692. doi: 10.3389/fneur.2018.00692. PubMed DOI PMC

Cheng Y., Ono M., Kimura H., Ueda M., Saji H. Technetium-99m Labeled Pyridyl Benzofuran Derivatives as Single Photon Emission Computed Tomography Imaging Probes for β-Amyloid Plaques in Alzheimer’s Brains. J. Med. Chem. 2012;55:2279–2286. doi: 10.1021/jm201513c. PubMed DOI

Jack C.R., Jr., Wiste H.J., Weigand S.D., Knopman D.S., Vemuri V.L.P., Mielke M.M., Jones D.T., Senjem M.L., Gunter J.L., Gregg B.E. Amyloid-first and neurodegeneration-first profiles characterize incident amyloid PET positivity. Neurology. 2013;12:1732–1740. doi: 10.1212/01.wnl.0000435556.21319.e4. PubMed DOI PMC

McKhann G.M., Knopman D.S., Chertkow H., Hyman B.T., Jack C.R., Jr., Kawas C.H. The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7:263–269. doi: 10.1016/j.jalz.2011.03.005. PubMed DOI PMC

Valotassiou V., Angelidis G., Psimadas D., Tsougos I., Georgoulias P. In the era of FDG PET, is it time for brain perfusion SPECT to gain a place in Alzheimer’s disease imaging biomarkers? Eur. J. Nucl. Med. Mol. Imaging. 2021;48:969–971. doi: 10.1007/s00259-020-05077-2. PubMed DOI

Hashimoto H., Nakanishi R., Mizumura S., Hashimoto Y., Okamura Y., Yamanaka K., Ikeda T. Prognostic value of 99mTc-ECD brain perfusion SPECT in patients with atrial fibrillation and dementia. EJNMMI Res. 2020;10:3. doi: 10.1186/s13550-019-0589-3. PubMed DOI PMC

Davison C.M., O’Brien J.T. A comparison of FDG-PET and blood flow SPECT in the diagnosis of neurodegenerative dementias: A systematic review. Int. J. Geriatr. Psychiatry. 2014;29:551–561. doi: 10.1002/gps.4036. PubMed DOI

Baker J.G., Williams A.J., Wack D.S., Miletich R.S. Correlation of Cognition and SPECT Perfusion: Easy Z Score and SPM Analysis of a Pilot Sample with Cerebral Small Vessel Disease. Dement. Gediatr.Cogn. Dis. 2013;36:290–299. doi: 10.1159/000339587. PubMed DOI

Jack C., Petersen R.C., Xu Y.C., O’Brien P.C., Smith G., Ivnik R.J., Boeve B.F., Waring S.C., Tangalos E.G., Kokmen E. Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment. Neurology. 1999;52:1397–1403. doi: 10.1212/WNL.52.7.1397. PubMed DOI PMC

Darcourt J., Booij J., Tatsch K., Varrone A., Borght T.V., Kapucu L., Någren K., Nobili F., Walker Z., Van Laere K. EANM procedure guidelines for brain neurotransmission SPECT using 123I-labelled dopamine transporter ligands, version 2. Eur. J. Nucl. Med. Mol. Imaging. 2010;37:443–450. doi: 10.1007/s00259-009-1267-x. PubMed DOI

Brown W.R., Moody D.M., Thore C.R., Challa V.R. Cerebrovascular pathology in Alzheimer’s disease and leukoaraiosis. Ann. N. Y. Acad. Sci. 2000;903:39–45. doi: 10.1111/j.1749-6632.2000.tb06348.x. PubMed DOI

Fernandez A.L., Abe J. Bias in cross-cultural neuropsychological testing: Problems and possible solutions. Cult. Brain. 2018;6:1–35. doi: 10.1007/s40167-017-0050-2. DOI

Te M., Zhao E., Xingyue Z., Qinjian S., Chuanqiang Q. Leukoaraiosis with mild cognitive impairment. Neurol. Res. 2014;37:410–414. doi: 10.1179/1743132815Y.0000000028. PubMed DOI

Kuo C.Y., Stachiv I. Biological mechanisms and possible primary prevention of depression. World J. Psychiatry. 2022;12:770–772. doi: 10.5498/wjp.v12.i5.770. PubMed DOI PMC

Rascovsky K., Hodges J.R., Knopman D., Mendez M.F., Kramer J.H., Neuhaus J., Van Swieten J.C., Seelaar H., Dopper E.G.P., Onyike C.U., et al. Sensitivity of revised diagnostic criteria for the behavioral variant of frontotemporal dementia. Brain. 2011;134:2456–2477. doi: 10.1093/brain/awr179. PubMed DOI PMC

Duclos H., Desgranges B., Eustache F., Laisney M. Impairment of social cognition in neurological diseases. Rev. Neurol. 2018;174:190–198. doi: 10.1016/j.neurol.2018.03.003. PubMed DOI

Baez S., Manes F., Huepe D., Torralva T., Fiorentino N., Richter F., Huepe-Artigas D., Ferrari J., Montaã±Es P., Reyes P.A., et al. Primary empathy deficits in frontotemporal dementia. Front. Aging Neurosci. 2014;6:262. doi: 10.3389/fnagi.2014.00262. PubMed DOI PMC

Koelkebeck K., Uwatoko T., Tanaka J., Kret M.E. How culture shapes social cognition deficits in mental disorders: A review. Soc. Neurosci. 2017;12:102–112. doi: 10.1080/17470919.2016.1155482. PubMed DOI

Kwon J.Y., Wormley A.S., Vaarnum E.W. Changing cultures, changing brains: A framework for integrating cultural neuroscience and cultural change research. Biol. Psychol. 2021;162:108087. doi: 10.1016/j.biopsycho.2021.108087. PubMed DOI

Chao S.Z., Rosen H.J., Azor V., Ong H., Tse M.M., Lai N.B., Hou C.E., Seeley W.W., Miller B.L., Matthews B.R. Frontotemporal dementia in eight Chinese individuals. Neurocase. 2013;19:76–84. doi: 10.1080/13554794.2011.654218. PubMed DOI PMC

Weekes B.S.H. Aphasia in Alzheimer’s disease and other dementias (ADOD): Evidence from Chinese. Am. J. Alzheimer’s Dis. Other Dement. 2020;35:1–12. doi: 10.1177/1533317520949708. PubMed DOI PMC

Tee B.L., Tempini M.L.G., Chen T., Lo R.Y., Wang P., Chan A.L., Chen L.L.K., Wong A., Yan C.T., Tsoh J., et al. Another side of the coin: Primary progressive aphasia in Chinese language. Alzheimers Dement. 2021;17:e052482. doi: 10.1002/alz.052482. DOI

Grube M., Bruffaerts R., Schaeverbeke J., Neyens V., De Weer A.-S., Seghers A., Bergmans B., Dries E., Griffiths T.D., Vandenberghe R. Core auditory processing deficits in primary progressive aphasia. Brain. 2016;139:1817–1829. doi: 10.1093/brain/aww067. PubMed DOI PMC

Harris J.M., Gall C., Thompson J.C., Richardson A.M., Neary D., du Plessis D., Pal P., Mann D.M., Snowden J.S., Jones M. Classification and pathology of primary progressive aphasia. Neurology. 2013;81:1832–1839. doi: 10.1212/01.wnl.0000436070.28137.7b. PubMed DOI